Search Within

Robin Beth Brenner

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (8)
  2. Center for Pancreatic Cancer Research (8)
  3. Department of Medicine (8)
  4. Epidemiology and Biostatistics (8)
  5. Gastrointestinal Oncology Service (8)
  6. Solid Tumor Oncology Division (8)

More Groups

People
  1. Eileen O'Reilly (8)
  2. Kenneth Yu (8)
  3. Marinela Capanu (8)
  4. David Kelsen (7)
  5. Joanne Chou (4)
  6. Maeve Lowery (4)

More People

Years
  1. 2023 (2)
  2. 2020 (2)
  3. 2018 (1)
  4. 2017 (2)
  5. 2016 (1)
Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer (2)
Publishers
  1. American Society of Clinical Oncology (6)
  2. Wiley Blackwell (2)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Lowery, M. A.; Capanu, M.; Stadler, Z. K.; Moore, M. J.; Dhani, N.; Kindler, H. L.; Estrella, H.; Maynard, H.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Meeting Abstract

    Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1B trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC)
    Meeting Abstract

    Lowery, M. A.; Capanu, M.; Glassman, D. C.; Covington, C. M.; Gluskin, J.; Brenner, R.; Li, C. F.; Bomalaski, J. S.; Johnston, A.; Barba, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save